Dealing with MDR bacteria and biofilm in the post-antibiotic era: Application of antimicrobial peptides-based nano-formulation

Song, Xinyu; Liu, Pengyan; Liu, Xiaohu; Wang, Yanan; Wei, Huichao; Zhang, Jingwen; Yu, Liangmin; Yan, Xuefeng; He, Zhiyu

doi:10.1016/j.msec.2021.112318

Cited by 32 publications

(18 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the nano-biomaterials have been suggested for the treatment of MDR-TB [ 130 ]. AMPs-based nano-formulations have significantly improved the therapeutic effects of AMPs in various bacterial infections models, including bloodstream (specifically sepsis), pulmonary, chronic wound, and gastrointestinal infections, by ameliorating their hydrolytic stability, in vivo half-life, and solubility, as well as reducing the cytotoxicity and hemolysis [ 131 ]. In summation, the most promising perspective on using nanotechnology resides in the possibility to wrap several types of drugs in nanocarriers and/or connect even different chemical substituents and specific substances on their surface to achieve optimal targeting, increase the drug stability and selectivity, and decrease the risk of undesired effects.…”

Section: Nanocarriersmentioning

confidence: 99%

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies

et al. 2022

View full text Add to dashboard Cite

Multidrug resistance is a leading concern in public health. It describes a complex phenotype whose predominant feature is resistance to a wide range of structurally unrelated cytotoxic compounds, many of which are anticancer agents. Multidrug resistance may be also related to antimicrobial drugs, and is known to be one of the most serious global public health threats of this century. Indeed, this phenomenon has increased both mortality and morbidity as a consequence of treatment failures and its incidence in healthcare costs. The large amounts of antibiotics used in human therapies, as well as for farm animals and even for fishes in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. It is not negligible that the ongoing COVID-19 pandemic may further contribute to antimicrobial resistance. In this paper, multidrug resistance and antimicrobial resistance are underlined, focusing on the therapeutic options to overcome these obstacles in drug treatments. Lastly, some recent studies on nanodrug delivery systems have been reviewed since they may represent a significant approach for overcoming resistance.

show abstract

Section: Nanocarriersmentioning

confidence: 99%

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…To avoid their degradation by peptidases/proteases in lungs, nanocarriers are commonly-used with great advantages. Carriers can prevent the self-aggregation of AMPs, and allow the release of the incorporated AMPs in a time-controllable manner by sustaining the degradation of the carriers, thus improving both their chemical stability and efficacy [ 60 ]. It has been reported that the stability of LLKKK18 AMP (an LL-37 analog) was enhanced in the formulation of hyaluronic acid nanogels [ 61 ].…”

Section: Emerging Inhaled Antibacterials For Respiratory Bacterial In...mentioning

confidence: 99%

Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment

Zheng

Leung

2022

Pharm Res

View full text Add to dashboard Cite

Bacterial infections in the respiratory tract are considered as one of the major challenges to the public health worldwide. Pulmonary delivery is an attractive approach in the management of bacterial respiratory infections with a few inhaled antibiotics approved. However, with the rapid emergence of antibiotic-resistant bacteria, it is necessary to develop new/alternative inhaled antibacterial agents in the post-antibiotic era. A pipeline of novel biological antibacterial agents, including antimicrobial peptides, RNAi therapeutics, and bacteriophages, has emerged to combat bacterial infections with excellent performance. In this review, the causal effects of bacterial infections on the related pulmonary infectious diseases will be firstly introduced. This is followed by an overview on the development of emerging antibacterial therapeutics for managing lung bacterial infections through nebulization/inhalation of dried powders. The obstacles and underlying proposals regarding their clinical transformation are also discussed to seek insights for further development. Research on inhaled therapy of these emerging antibacterials are still in the infancy, but the promising progress warrants further attention.

show abstract

“…Bacteria embedded in these bacterial communities often have 1000-fold increased tolerance to antibiotics. Moreover, there are no antimicrobials specifically targeting biofilm eradication approved by the major regulatory agencies [5,6]. Antimicrobial peptides (AMPs) are often considered promising candidates to mitigate the effects and progression of AMR [7,8].…”

Section: Introductionmentioning

confidence: 99%

“…The antimicrobial activity of AMPs is often broad, including gram-positive and gramnegative bacteria, viruses, and fungi [12,13]. Additionally, AMPs and other MAAs could improve the eradication of biofilm-embedded bacteria compared to the more conventional antimicrobials [6].…”

Section: Introductionmentioning

confidence: 99%

Tailored anti-biofilm activity – Liposomal delivery for mimic of small antimicrobial peptide

Hemmingsen

Giordani

Paulsen

et al. 2023

Biomaterials Advances

View full text Add to dashboard Cite

Dealing with MDR bacteria and biofilm in the post-antibiotic era: Application of antimicrobial peptides-based nano-formulation

Cited by 32 publications

References 196 publications

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies

Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment

Tailored anti-biofilm activity – Liposomal delivery for mimic of small antimicrobial peptide

Contact Info

Product

Resources

About